My research today was a journal article titled...A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer
...which led me to Olympus. They seem to have a very positive review in that article. A lot of gargling it seems needed for the process. Naturally Olympus has a quality product though. How it compares to Optiscan.... Perhaps someone on here can enlighten.
But that led me to look into what else is being developed..
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287312/
There seems to be a lot more out there than I expected, so I couldn't get through much of that article.
But with a few other more general articles on the future of demand for oral, breast, and brain cancer diagnosis and treatment in the next decade and beyond, once hospitals can start doing elective surgeries again, if Optiscan can get three quality products on the market, even a small market share will see nice annual profits.
Add to My Watchlist
What is My Watchlist?
